全球生技药品市场按产品、药物类别、给药途径、采购形式、分销管道和地区划分

2025 年全球生技药品市场规模估计为 5.775 亿美元，预计到 2032 年将达到 11.698 亿美元，2025 年至 2032 年的复合年增长率为 10.6%。

市场占有率。

生技药品是由生物体製成的药物，用于预防、治疗或治癒人类疾病。其中包括疫苗、血液成分、过敏原、体细胞、基因疗法、组织和重组治疗性蛋白质。全球慢性病盛行率不断上升，加上易患各种疾病的老年人口不断增加，可能会增加对生技药品的需求。生物技术的快速创新和进步使得开发安全性、有效性和作用特异性更高的新型生物製药成为可能。这扩大了多种危及生命的疾病的治疗选择，包括癌症、风湿病和自体免疫疾病。扩大监管核准和生技药品商业化可能会推动市场成长。

市场动态

全球生技药品市场的成长得益于糖尿病、癌症和心血管疾病等慢性病在全球的盛行率不断上升，以及医疗保健对生技药品研发支出的不断增加。此外，对蛋白质类药物的需求不断增加、先进生技药品的快速核准以及强劲的新型生技药品候选产品线也在推动市场成长。生物加工和品质分析技术的不断进步，促进了高产生产平台的开发，有利于商业规模上经济高效地生产生技药品。然而，建立生物製造设施所需的大量资本投入、严格的监管标准以及生物分子的复杂性对开发生物相似药构成了挑战。亚太和拉丁美洲等新兴市场为相关人员探索新市场和抵销市场限制提供了有利可图的机会。

本研究的主要特点

本报告对全球生技药品市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和复合年增长率。

它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球生技药品市场的主要企业已根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行了分析。

研究涉及的主要企业包括 F. Hoffmann-La Roche、AbbVie、安进、强生服务公司、默克、辉瑞、赛诺菲、吉利德科学、诺华、百时美施贵宝、再生元、武田工业、百健、礼来公司和 Celltrion Healthcare。

本报告的见解可以帮助负责人和企业经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。

全球生技药品市场报告迎合了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员将透过分析全球生技药品市场所使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特的分析
• 併购情景
• 产业趋势

4. 全球生技药品市场（依产品划分） (2020-2032)

• 单株抗体
• 疫苗
• 重组荷尔蒙/蛋白质
• 基于细胞的生技药品
• 基于基因的生技药品
• 其他的

5. 全球生技药品市场依药物类别划分（2020-2032 年）

• 品牌药物
• 学名药

6. 依给药途径分類的全球生技药品市场（2020-2032 年）

• 口服
• 肠外
• 其他路线

7. 全球生技药品市场依购买类型划分（2020-2032 年）

• 处方药
• 非处方药

8. 全球生技药品市场依通路划分（2020-2032 年）

• 院内药房
• 零售药局
• 网路药局

9. 全球生技药品市场（按地区划分） (2020-2032)

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi SA
• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Eli Lilly and Company
• Celltrion Healthcare Co., Ltd.

第 11 章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Biologics Market is estimated to be valued at USD 577.5 Mn in 2025 and is expected to reach USD 1,169.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.

Figure. Biologics Market Share (%), By Region 2025

Biologics refers to medicines created from living organisms that are used to prevent, treat, and cure human diseases. These include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Increasing prevalence of chronic diseases worldwide coupled with rising elderly population prone to various illnesses can boost demand for biologics. Rapid innovations and advancements in biotechnology have enabled development of novel biologic agents with improved safety, efficacy and specificity of action. This has expanded treatment options for several life-threatening conditions such as cancer, rheumatic disorders, and autoimmune diseases. Growing regulatory approvals and commercialization of biologics can drive the market growth.

Market Dynamics

Global biologics market growth is driven by growing prevalence of chronic diseases worldwide such as diabetes, cancer, cardiovascular diseases along with rising healthcare expenditure on biopharmaceutical R&D. Increasing demand for protein-based drugs, rapid approvals of advanced biologics and strong pipeline of novel biologic candidates can also drive the market growth. Constant technological advancements in bioprocessing and quality analytics enables development of high-yield production platforms conducive for cost-effective manufacturing of biologics at commercial scale. However, factors such as high capital investment needs for setting up bio-manufacturing facilities, stringent regulatory norms, and complexity of biological molecules poses challenges in biosimilar development. Emerging markets across developing regions such as Asia Pacific and Latin America offer lucrative opportunities for stakeholders to tap into new geographic territories and offset restraint impact.

Key Features of the Study

This report provides in-depth analysis of the global biologics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biologics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Eli Lilly and Company, and Celltrion Healthcare Co., Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics market

Market Segmentation

• By Product Insights (Revenue, USD Mn, 2019 - 2032)
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cellular-based Biologics
  • Gene-based Biologics
  • Others
• By Drug Classification Insights (Revenue, USD Mn, 2019 - 2032)
  • Branded Drugs
  • Generic Drugs
• By Route of Administration Insights (Revenue, USD Mn, 2019 - 2032)
  • Oral
  • Parenteral
  • Other Routes
• By Mode of Purchase Insights (Revenue, USD Mn, 2019 - 2032)
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
• By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2019 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Eli Lilly and Company
  • Celltrion Healthcare Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Biologics Market, By Product
  • Global Biologics Market, By Drug Classification
  • Global Biologics Market, By Route of Administration
  • Global Biologics Market, By Mode of Purchase
  • Global Biologics Market, By Distribution Channel
  • Global Biologics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Biologics Market, By Product, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Recombinant Hormones/Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Cellular-based Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Gene-based Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Biologics Market, By Drug Classification, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Branded Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Generic Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Biologics Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Other Routes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Biologics Market, By Mode of Purchase, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Prescription-Based Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Over-The-Counter Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Biologics Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Biologics Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Drug Classification, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Mode of Purchase, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson Services, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi S.A.
• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Eli Lilly and Company
• Celltrion Healthcare Co., Ltd.

11. References and Research Methodology

• References
• Research Methodology
• About us